A notice from Johnson & Johnson (J&J) was posted on the HRSA website stating that J&J will be issuing refunds to covered entities for overcharges on certain drugs sold between January 1, 2017 through February 9, 2017. 

J&J stated that it “will be communicating with and issuing refund adjustments through wholesalers that submitted the original sale on behalf of the 340B covered entities.”   Covered entities should contact J&J if they believe that they have not received an appropriate adjustment.

The refunded drugs include the following medications commonly provided to HIV patients: